Pricing Log in Create free account

Immunome, Inc. (IMNM) vs Palvella Therapeutics, Inc. (PVLA)

Immunome, Inc. and Palvella Therapeutics, Inc. are both Biotechnology companies. Immunome, Inc. and Palvella Therapeutics, Inc. are of similar size ($2.3B and $2.1B). Palvella Therapeutics, Inc. grew revenue faster over the last twelve months: 146.7% against 16.7%. Across the 12 metrics below, Palvella Therapeutics, Inc. leads on 11 and Immunome, Inc. on 1.

Valuation

Metric IMNM PVLA Biotechnology median
P/E n/m n/m 10.26
P/S 162.50 54.15 9.18
P/B 3.90 10.38 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 121.23 48.15 8.98
Earnings yield (14.01%) (3.08%) (34.89%)
Free cash flow yield (10.71%) (1.43%) (24.52%)

Profitability

Metric IMNM PVLA Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (64.03%) (46.63%) (50.12%)
Return on assets (59.03%) (37.70%) (45.60%)
Return on invested capital (3,322.99%) 0.00% 0.00%

Growth

Metric IMNM PVLA Biotechnology median
Revenue growth (TTM) 16.74% 146.67% 6.26%
EPS growth (last fiscal year) 51.40% 52.62% 29.88%
Revenue growth, 5-year CAGR — 8.03% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMNM PVLA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 15.08 21.18 4.89
Net debt to EBITDA 2.92 1.50 1.01

Dividend

Metric IMNM PVLA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric IMNM PVLA Biotechnology median
Market cap 2.11b 2.26b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack